WEBINAR: USING THE PARSORTIX^TM SYSTEM TO IDENTIFY DRUGS THAT MAY ARREST CANCER METASTASIS

GUILDFORD, SURREY / ACCESSWIRE / January 16, 2018 / ANGLE plc ("the Company") (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that Professor Stuart Martin from the University of Maryland School of Medicine, USA, will be presenting a webinar describing his breakthrough work using the Parsortix^TM system to test drugs on live circulating tumor cells (CTCs) as was described in the Company's announcement on 9 October 2017.

The webinar is intended for cancer researchers but is also open to investors and other interested parties. The details are as follows:

"Microfluidic Cell Tethering Enables Rapid Analysis of Drug Responses in Live Patient CTCs"

Wednesday 17 January 2018 from 5pm to 5:50pm UK time. Participants need to register in advance using the following link

https://register.gotowebinar.com/register/5646294960950153218

Over 90% of deaths from cancer arise from the process of metastasis where the cancer spreads throughout the body via CTCs in the blood causing secondary cancers. If drugs can be identified for the patient that disable their CTCs then the metastatic spread of the disease might be arrested or reduced.

For further information ANGLE:

ANGLE plc
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
+44 (0) 1483 343434

finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Adrian Hargrave, Simon Hicks, Kate Bannatyne
Corporate Broking - Alice Lane, Nikita Jain
+44 (0)20 7220 0500

WG Partners (Joint Broker)
Nigel Barnes
Nigel Birks
+44 (0) 203 705 9318
+44 (0) 203 705 9316

FTI Consulting
Simon Conway, Mo Noonan, Stephanie Cuthbert
Kimberly Ha (US)
+44 (0) 203 727 1000
+1 212 850 5612

For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/

Notes for editors

About ANGLE plc www.angleplc.com

ANGLE is a world-leading liquid biopsy company commercializing a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.

ANGLE's cell separation technology is called the Parsortix ^TM system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix^TM is the subject of granted patents in Europe, the United States, Canada, India, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. Parsortix^TM has a CE Mark for Europe and FDA authorisation is in process for the United States.